Related Experiment Videos
Morphine at gramme doses: kinetics, dynamics and clinical need
K J Smith1, A J Miller, J McKellar
1Napp Laboratories Ltd., Cambridge, UK.
Postgraduate Medical Journal
|January 1, 1991
Summary
The new 200 mg MS Contin tablet offers equivalent morphine sulphate absorption and analgesia compared to two 100 mg tablets. This higher strength formulation simplifies dosing for patients needing larger morphine amounts.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Pain Management
Background:
- MS Contin (controlled release morphine sulphate) is a key analgesic.
- Existing formulations include 100 mg tablets.
- Higher doses are often required for effective pain management.
Purpose of the Study:
- To evaluate the pharmacokinetic and pharmacodynamic equivalence of a new 200 mg MS Contin tablet.
- To compare the 200 mg formulation against two 100 mg tablets.
- To assess the suitability of the 200 mg tablet for dose escalation.
Main Methods:
- Bioequivalence study comparing absorption rates and extents.
- Pharmacodynamic assessment of analgesia over a 12-hour dosing interval.
- Analysis of controlled release characteristics of the 200 mg formulation.
Main Results:
- The 200 mg MS Contin tablet demonstrated equivalent rate and extent of absorption to two 100 mg tablets.
- Controlled release characteristics were consistent between the 100 mg and 200 mg formulations.
- Equivalent levels of analgesia were observed across the dosing period.
Conclusions:
- The 200 mg MS Contin tablet is bioequivalent to two 100 mg tablets.
- This new strength facilitates oral administration for patients requiring higher morphine sulphate doses.
- It offers clinicians greater flexibility in dose titration for effective pain management.